Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Raskin, Jo
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer	Recruiting	3	700	Europe, Japan, US, RoW	Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo	Eli Lilly and Company, AstraZeneca	Carcinoma, Non-Small-Cell Lung	05/29	02/32
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)	Active, not recruiting	1/2	61	Europe, Japan, US, RoW	M1774, Tuvusertib, Cemiplimab	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Non-Small Cell Lung Cancer	05/25	02/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Raskin, Jo
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer	Recruiting	3	700	Europe, Japan, US, RoW	Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo	Eli Lilly and Company, AstraZeneca	Carcinoma, Non-Small-Cell Lung	05/29	02/32
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)	Active, not recruiting	1/2	61	Europe, Japan, US, RoW	M1774, Tuvusertib, Cemiplimab	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Non-Small Cell Lung Cancer	05/25	02/26